Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy

Clinical Genitourinary Cancer

Volumn 13, Issue 1, 2015, Pages 22-31

  Singal, Rakesh ^a   Ramachandran, Kavitha ^a   Gordian, Edna ^a   Quintero, Carlos ^a   Zhao, Wei ^a   Reis, Isildinha M ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Chemotherapy; GADD45A; Methylation; Taxotere; Vidaza

Indexed keywords

AZACITIDINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN GADD45A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; GADD45A PROTEIN, HUMAN; NUCLEAR PROTEIN; TAXOID;

ACIDOSIS; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DEMETHYLATION; DIARRHEA; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GENE SILENCING; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPONATREMIA; HYPOTENSION; INFARCTION; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SEPSIS; THORAX PAIN; TREATMENT RESPONSE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CELL CYCLE PROTEINS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84920374465     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.07.008     Document Type: Article

References (21)

1. D.P. Petrylak, C.M. Tangen, and M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
2. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
3. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
4. K. Fizazi, H.I. Scher, and A. Molina Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
5. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
6. C. Parker, S. Nilsson, and D. Heinrich Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
7. Y. Li, X. Li, M. Hussain, and F.H. Sarkar Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray Neoplasia 6 2004 158 167
8. K. Ramachandran, G. Gopisetty, and E. Gordian Methylation-mediated repression of GADD45 alpha in prostate cancer and its role as a potential therapeutic target Cancer Res 69 2009 1527 1535
9. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
10. P.M. Das, K. Ramachandran, and J. Vanwert Methylation mediated silencing of TMS1/ASC gene in prostate cancer Mol Cancer 5 2006 28
11. G.J. Bubley, M. Carducci, and W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467
12. H.I. Scher, S. Halabi, and I. Tannock Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
13. P.M. Das, and R. Singal DNA methylation and cancer J Clin Oncol 22 2004 4632 4642
14. L.R. Silverman, D.R. McKenzie, and B.L. Peterson Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 24 2006 3895 3903
15. J.M. Quagliana, R.M. O'Bryan, and L. Baker Phase II study of 5-azacytidine in solid tumors Cancer Treat Rep 61 1977 51 54
16. A. Thibault, W.D. Figg, and R.C. Bergan A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer Tumori 84 1998 87 89
17. G. Sonpavde, A.M. Aparicio, and F. Zhan Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration-resistant prostate cancer Urol Oncol 29 2011 682 689
18. Y. Huang, P. Anderle, and K.J. Bussey Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance Cancer Res 64 2004 4294 4301
19. S. Fu, W. Hu, and R. Iyer Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer Cancer 117 2011 1661 1669
20. K. Ramachandran, H. Miller, E. Gordian, C. Rocha-Lima, and R. Singal Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity Anticancer Res 30 2010 3919 3925
21. K. Ramachandran, E. Gordian, and R. Singal 5-Azacytidine reverses drug resistance in bladder cancer cells Anticancer Res 31 2011 3757 3766